Jasper Therapeutics Inc. (JSPR)
Jasper Therapeutics Statistics
Share Statistics
Jasper Therapeutics has 15.02M shares outstanding. The number of shares has increased by -0.42% in one year.
| Shares Outstanding | 15.02M |
| Shares Change (YoY) | -0.42% |
| Shares Change (QoQ) | 0.14% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 11.88M |
| Failed to Deliver (FTD) Shares | 416 |
| FTD / Avg. Volume | 0.14% |
Short Selling Information
The latest short interest is 1.87M, so 12.47% of the outstanding shares have been sold short.
| Short Interest | 1.87M |
| Short % of Shares Out | 12.47% |
| Short % of Float | 12.63% |
| Short Ratio (days to cover) | 9.26 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.93. Jasper Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -0.93 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 5.06 |
| P/FCF Ratio | -4.94 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Jasper Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.98, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.98 |
| Quick Ratio | 4.98 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $0 |
| Employee Count | 64 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -79.3% in the last 52 weeks. The beta is 2.56, so Jasper Therapeutics's price volatility has been higher than the market average.
| Beta | 2.56 |
| 52-Week Price Change | -79.3% |
| 50-Day Moving Average | 5 |
| 200-Day Moving Average | 14.91 |
| Relative Strength Index (RSI) | 50.84 |
| Average Volume (20 Days) | 306.7K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -76.24M |
| Net Income | 0 |
| EBITDA | -76.24M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -4.89 |
Balance Sheet
The company has 71.64M in cash and 1.81M in debt, giving a net cash position of 69.82M.
| Cash & Cash Equivalents | 71.64M |
| Total Debt | 1.81M |
| Net Cash | 69.82M |
| Retained Earnings | -240.87M |
| Total Assets | 79.9M |
| Working Capital | 60.57M |
Cash Flow
In the last 12 months, operating cash flow was -62.6M and capital expenditures -552K, giving a free cash flow of -63.15M.
| Operating Cash Flow | -62.6M |
| Capital Expenditures | -552K |
| Free Cash Flow | -63.15M |
| FCF Per Share | -4.33 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
JSPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for JSPR is $64, which is 1303.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $64 |
| Price Target Difference | 1303.5% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Stock Splits
The last stock split was on Jan 4, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jan 4, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -1.26 |
| Piotroski F-Score | 0 |